Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06047028 · ClinicalTrials.gov registry record

Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability

A clinical trial of Coronary Artery Disease and Ischemic Heart Disease (IHD), sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
30
Enrollment target
1
Study location

NCT06047028: Recruiting study of Coronary Artery Disease and Ischemic Heart Disease (IHD), sponsored by University of Texas Southwestern Medical Center.

NCT06047028 is a study of Coronary Artery Disease and Ischemic Heart Disease (IHD) that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06047028, a study of Coronary Artery Disease and Ischemic Heart Disease (IHD), is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

Heart failure due to coronary artery disease represents a significant cause of mortality. The detection of patients eligible for bypass surgery is a pivotal concern. Nevertheless, the optimal approach for patient selection based on conventional imaging scans remains unclear. The proposed method (Hyperpolarized 13C MRI) has gained extensive use in evaluating in vivo metabolism. This method avoids ionizing radiation and provides critical insights into cardiac function. The feasibility study aims to investigate this method for patient selection before bypass surgery. This innovative imaging technique facilitates the identification of two simple molecules, bicarbonate and lactic acid, produced at high rates by normal heart metabolism. Both bicarbonate and lactate originate from the same precursor molecule, pyruvate. The data generated from this study holds the potential to refine diagnostic precision.

Primary Outcome

Assessment of normal segmental myocardial metabolism by measuring the ratio of hyperpolarized (HP) \[13C\]-bicarbonate to HP \[1-13C\]lactate (bic/lac ratio). This is obtained during an HP-13C MRI utilizing \[1-13C\] pyruvate to establish baseline normal values for healthy subjects.

Study Locations (1)

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-06-30
Est. Completion 2026-06-30

What NCT06047028 shows while recruiting

NCT06047028 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 0 interventions.

NCT06047028 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06047028 about?

NCT06047028 is a clinical study titled "Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability". Heart failure due to coronary artery disease represents a significant cause of mortality. The detection of patients eligible for bypass surgery is a pivotal concern. Nevertheless, the optimal approach for patient selection based on conventional imaging scans remains unclear. The proposed method (Hyp...

What is the current status of trial NCT06047028?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-06-30. Estimated completion is 2026-06-30.

What conditions does trial NCT06047028 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Ischemic Heart Disease (IHD), Myocardial Viability.

Who is sponsoring clinical trial NCT06047028?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06047028 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06047028's enrollment target sits among peer trials

30 198th of 219 higher than 17 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06047028, the US trial registry maintained by the National Library of Medicine. NCT06047028 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.